National

ETV Bharat / bharat

TOP 10 @ 9 PM

Drugs Controller General of India has given approval to Serum Institute of India at Pune to conduct Phase II and III clinical trials of Oxford University - Astra Zeneca COVID19 vaccine in India. Meanwhile, actor Rhea Chakraborty is not absconding, her lawyer has clarified after several reports claimed that she has gone missing over the past few days. This and more, get to know the top national stories at a glance.

TOP 10 @ 9 PM
TOP 10 @ 9 PM

By

Published : Aug 3, 2020, 9:02 PM IST

1. Govt allows Serum Institute for phase 2 and 3 clinical trial of COVID-19 vaccine

Drugs Controller General of India has given approval to Serum Institute of India at Pune to conduct Phase II and III clinical trials of Oxford University - Astra Zeneca COVID19 vaccine in India. The SII is likely to begin the trials shortly with around 4000 to 5000 volunteers.

2. Advani, MM Joshi likely to join 'bhoomi pujan' of Ram Temple through video conferencing

Senior BJP leaders LK Advani and Murli Manohar Joshi are likely to join the 'bhoomi pujan' of the Ram Temple in Ayodhya on August 5 through video conferencing due to health conditions, sources said.

3. Govt issues guidelines for reopening of gyms, yoga institutes

The Health Ministry on Monday issued protocols ahead of the reopening of yoga institutions and gymnasiums. The protocols include allowing only asymptomatic people, maintaining social distancing, use of Aarogya Setu mobile application and the wearing of visor while exercising.

4. Bihar DGP will speak to Maharashtra police on SP being quarantined in Mumbai

Bihar Chief Minister Nitish Kumar on Monday said that the state Director General of Police (DGP) Gupteshwar Pandey will speak to the Maharashtra Police as regards the quarantining of Patna SP Vinay Tiwari in Mumbai.

5. PM Modi, Afghan President Ghani discuss evolving security situation

Prime Minister Narendra Modi and Afghanistan President Ashraf Ghani discussed the evolving security situation in the region and other areas of mutual and bilateral interest on Monday.

ABOUT THE AUTHOR

...view details